HS-10382

N/A

Report date: 2026/04/16 20:00:17
NME

Base Information

Drug NameHS-10382
Drug Alias NameHS-10382TERN-701
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitorsProtein allosteric inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myeloid, Chronic-PhaseLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandItaly +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Hansoh Pharmaceutical Group Co LtdShanghai Hansoh Biomedical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHansoh Pharmaceutical Group Company LtdJiangsu Hansoh Pharmaceutical Group Co LtdShanghai Hansoh Biomedical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Chronic-PhaseLeukemia, Myelogenous, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A